Stephen Elledge's Harvard lab takes $17M to birth ImmuneID, a high-throughput antibody startup

Nicole DeFeudis

Editor

Lea Hachigian, a principal at the Longwood Fund, recalls working with Harvard professor Stephen Elledge three years ago on the launch of TCR-focused TScan Therapeutics …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Stephen Elledge's Harvard lab takes $17M to birth ImmuneID, a high-throughput antibody startup

Nicole DeFeudis

Editor

Sign up to read this article for free.

Norbert Bischofberger's time as Kronos CEO ends as biotech seeks new life

Novartis to cut 139 jobs in NJ as part of commercial refocus

Applied Therapeutics' rare disease drug gets a CRL

Bristol Myers sues the federal government over 340B, following other drugmakers

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

Sarepta licenses Arrowhead's RNA-based rare disease pipeline, promising big biobucks

Stephen Elledge's Har­vard lab takes $17M to birth Im­muneID, a high-through­put an­ti­body start­up

Nicole DeFeudis

Editor

Sign up to read this article for free.

more like this

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

Stephen Elledge's Harvard lab takes $17M to birth ImmuneID, a high-throughput antibody startup

Norbert Bischofberger's time as Kronos CEO ends as biotech seeks new life

Novartis to cut 139 jobs in NJ as part of commercial refocus

Applied Therapeutics' rare disease drug gets a CRL

Bristol Myers sues the federal government over 340B, following other drugmakers

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

Sarepta licenses Arrowhead's RNA-based rare disease pipeline, promising big biobucks